3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Urinary Bladder Neoplasms
1
Non-Muscle Invasive Bladder Neoplasms
1
Carcinoma in Situ
1
Interventions
Gemcitabine
11
Magnetic Resonance Spectroscopy
10
Specimen Handling
8
Cisplatin
7
pembrolizumab
6
Radiation
5
Mitomycin
4
Fluorouracil
4
Cystoscopy
4
enfortumab vedotin
3
durvalumab
3
dehydroftorafur
3
avelumab
3
Transurethral Resection of Bladder
3
Radiotherapy
3
Platinum
3
Nivolumab
3
Mitozytrex
3
Cystectomy
3
1,2-diaminocyclohexaneplatinum II citrate
3
ulixertinib
2
tremelimumab
2
erdafitinib
2
atezolizumab
2
Paclitaxel
2
Immunoglobulin G
2
Docetaxel
2
Disulfides
2
Carboplatin
2
Biopsy
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urinary Bladder Neoplasms
×
BCG Vaccine
×
30 days
×
Clear all
NCT06833073
2026-05-28
INTerpath-011
Merck Sharp & Dohme LLC
Phase 2
Recruiting
308 enrolled